Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, the number of randomised, controlled clinical trials is small. Much of the published information is based on open-label studies or anecdotal data. Of the robust trial data that is available, the vast majority relates to the treatment of glabellar lines, and there is little data available regarding the use of BoNT-A in lateral canthal lines. This study aims to determine the optimum dose for the use of BoNT-A in this area.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
221
Clinique Bel Air
Bordeaux, France
Centre Hospitalier Universitaire de Nice
Nice, France
Service de Chirurgie Maxillo Faciale
Saint-Cloud, France
Charite-Universitatsmedizin Berlin
Berlin, Germany
Change in severity of crow's feet at maximum smile at week 4, compared to baseline, assessed photographically by independent panel
At week 2,4,8,12,16,20,24, compared to baseline: change in severity of crow's feet at rest & max. smile, assessed by investigator & independent panel (photographically); change in patient satisfaction with appearance of crow's feet & general appearance
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dermatologie, Stadt. Klinikum Dresden-Friedrichstadt
Dresden, Germany
Universitats - Hautklinik
Homburg, Germany
The Cambridge Private Hospital
Cambridge, England, United Kingdom
Harley Street
London, England, United Kingdom
The Golden Jubilee National Hospital
Clydebank, Scotland, United Kingdom